• Exclusive agreement to evaluate ginseng-based formulation for male vitality and performance
• 6-month exclusivity period to conduct due diligence and product testing
• Potential to acquire IP rights and engage developer as R&D consultant

BPH Global Ltd (ASX: BP8) has executed a Confidentiality and Exclusivity Agreement with Denmark-based scientist Jo-an Refugio to facilitate the evaluation and potential acquisition of a proprietary ginseng-based formulation developed by Jo-an. Under the agreement, BPH Global has secured a six-month exclusivity period commencing 5 November 2025 to conduct technical and laboratory testing of the formulation, including impurity and stability assessments, to evaluate its suitability for commercialisation. The exclusivity arrangement also provides a framework for the parties to negotiate terms for a commercial agreement, under which BPH Global may acquire intellectual property rights to the formulation and consider engaging Jo-an as an R&D consultant to assist in further development and optimisation of the product. The proprietary formulation, developed in accordance with Traditional Chinese Medicine (TCM) principles, includes Panax ginseng as a key ingredient together with other complementary herbal components. The product is designed to support male vitality and overall wellbeing through natural mechanisms associated with healthy circulation and energy balance. The formulation forms part of the Company's broader R&D initiative exploring two development pathways: natural Over-the-Counter (OTC) products and evidence-based, clinically tested products.

During the six-month exclusivity period, the Company will conduct due diligence testing on the ginseng-based formulation and evaluate commercial terms for a definitive agreement with Jo-an. Further updates will be provided as material developments occur.